OpenAlex
PricingAboutJobs
Log inGet started
Work

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

HTML

Year: 2020
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-19-0183
Authors: Shripad V. Bhagwat, William T. McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Weihua Shen, Lisa Kindler, Robert S. Flack, Wenjuan Wu, Bryan Anderson, Yan Zhai, Xiu-Juan Yuan, Meghann Pogue, Robert D. Van Horn, Xi Rao, Denis McCann, Andrew J. Dropsey, Jason Manro, Jennie Walgren, Eunice Yuen, Michael J. Rodriguez, Gregory D. Plowman, Ramon V. Tiu, Sajan Joseph, Sheng-Bin Peng
Institution: Eli Lilly (United States)
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: LY3214996, ERK inhibitor, ERK signaling, KRAS-mutant cancer, acquired drug resistance, pharmacodynamic biomarkers, colorectal cancer, xenograft models, precision oncology
SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company
OpenAlex ID: W2990581152
FWCI: 4.173
Cites: 44
Cited by: 121
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security